

**S8 Table.** Clinical characteristics of ERG, LRG, and NRG among *EGFR*-mutant stage IA (AJCC 7th edition) patients (n=390)

Characteristic	ERG (n=6)	LRG (n=24)	NRG (n=360)	p-value
<b>Age (yr)</b>				0.032
≤ 65	2 (33.3)	11 (45.8)	226 (62.8)	
> 65	4 (66.7)	13 (54.2)	134 (37.2)	
<b>BMI (kg/m<sup>2</sup>)</b>	22.40±1.40	23.14±2.13	23.99±3.15	0.203
<b>Sex</b>				0.060
Male	5 (83.3)	9 (37.5)	124 (34.4)	
Female	1 (16.7)	15 (62.5)	236 (65.6)	
<b>Smoking status</b>				0.792
Never	3 (50.0)	19 (79.2)	276 (76.7)	
Ever	3 (50.0)	5 (20.8)	82 (22.8)	
Unknown	0	0	2 (0.6)	
<b>ECOG</b>				0.944
0-1	6 (100)	20 (83.3)	322 (89.4)	
≥ 2	0	0	4 (1.1)	
Unknown	0	4 (16.7)	34 (9.4)	
<b>PFT</b>				
FVC (L)	3.36±1.02	3.24±0.86	3.24±0.86	0.939
FEV1 (L)	2.27±0.53	2.44±0.65	2.48±0.69	0.742
DLco (%)	89.50±26.51	93.33±14.63	94.90±17.55	0.707
<b>Pathologic T stage</b>				0.211
T1a	2 (33.3)	11 (45.8)	209 (58.1)	
T1b	4 (66.7)	13 (54.2)	143 (39.7)	
T1 NOS	0	0	8 (2.2)	
<b>Surgery type</b>				0.267
Wedge resection	1 (16.7)	4 (16.7)	38 (10.6)	
Segmentectomy	1 (16.7)	4 (16.7)	47 (13.1)	
Lobectomy	4 (66.7)	16 (66.7)	274 (76.1)	
Pneumonectomy	0	0	1 (0.3)	
<b>Histologic type</b>				0.193
Squamous	1 (16.7)	1 (4.2)	7 (1.9)	
Adenocarcinoma	5 (83.3)	23 (95.8)	350 (97.2)	
Adenosquamous	0	0	1 (0.3)	
Others	0	0	2 (0.6)	
<b>Mediastinal LN resection</b>				> 0.99
No	0	1 (4.2)	21 (5.8)	
Sampling	1 (16.7)	2 (8.3)	31 (8.6)	
Dissection	5 (83.3)	21 (87.5)	306 (85.0)	
Unknown	0	0	2 (0.6)	
<b>ALK</b>				0.576
Positive	0	2 (8.3)	6 (1.7)	
Negative	5 (83.3)	17 (70.8)	298 (82.8)	
Unknown	1 (16.7)	5 (20.8)	56 (15.6)	
<b>Chemotherapy</b>				< 0.001
Adjuvant	4 (66.7)	10 (41.7)	6 (1.7)	
None	2 (33.3)	14 (58.2)	354 (98.3)	
<b>RT</b>				< 0.001
Adjuvant	3 (50.0)	4 (16.7)	6 (1.7)	
None	3 (50.0)	20 (83.3)	354 (98.3)	
<b>Observation time (mo)</b>	33.61±14.07	37.97±9.40	37.47±10.88	0.651

<b>Recurrence-free survival time (mo)</b>	12.06±10.98	24.25±10.47	37.33±10.88	< 0.001
---	-------------	-------------	-------------	---------

---

Values are presented as number (%) or mean±SD. The significance level of p-value was set after Bonferroni correction. AJCC, American Joint Commission on Cancer; ALK, anaplastic lymphoma kinase; ALK positive, ALK immunohistochemistry or fluorescence *in situ* hybridization positive; BMI, body mass index; DLco, diffusing capacity of the lungs for carbon monoxide; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; ERG, early recurrence group; FEV<sub>1</sub>, forced expiratory volume exhaled in the first second; FVC, forced vital capacity; LN, lymph node; LRG, late recurrence group; NOS, not otherwise specified; NRG, no recurrence group; PFT, pulmonary function test; RT, radiotherapy.